Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Krystal Biotech (KRYS)
NASDAQ:KRYS
Krystal Biotech (KRYS) Stock Price & Analysis
426 Followers
KRYS Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$93.95 - $214.98
Previous Close$203.66
Volume277.23K
Average Volume (3M)397.21K
Market Cap
$5.82B
Enterprise Value$5.29B
Total Cash (Recent Filing)$532.18M
Total Debt (Recent Filing)$8.09M
Price to Earnings (P/E)108.2
Beta0.79
Next Earnings
Nov 04, 2024EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.88
Shares Outstanding28,558,440
10 Day Avg. Volume1,015,802
30 Day Avg. Volume397,211
Standard Deviation0.16
R-Squared0.09
Alpha0.03
Financial Highlights & Ratios
Price to Book (P/B)6.41
Price to Sales (P/S)118.47
Price to Cash Flow (P/CF)-172.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue104.29
Enterprise Value/Gross Profit111.17
Enterprise Value/Ebitda50.47
Forecast
1Y Price Target
$204.00Price Target Upside0.17% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Krystal Biotech News
PremiumCompany Announcements
Krystal Biotech Reveals Eye Treatment Vector at ARVO 2024
Bulls Say, Bears Say
Bulls Say
Financial PerformanceKrystal Biotech's strong financial foundation is highlighted by its robust cash position, providing a solid base for future operations and investments.
Gene Therapy AdvancementsKrystal Biotech's HSV-1 gene therapy vector shows promise for posterior eye delivery, offering an innovative avenue for further therapeutic developments.
Pipeline PotentialKrystal Biotech expects to deliver data readouts showcasing the breadth and potential of its proprietary HSV-1 based gene delivery platform, signaling future growth and expansion into new therapeutic areas.
Bears Say
EarningsKrystal announced 1Q24 results, posting EPS of $0.03 compared to an estimate of $0.09 and consensus of $0.27.
Financial PerformanceThere was an expected, one-time headwind due to the permanent J code switch, which had significant impacts on reimbursement and an expected negative impact on revenue projections.
Management And OperationsConcerns for the commercial execution in the absence of a Chief Commercial Officer.
---
Ownership Overview
23.57% Insiders
33.13% Mutual Funds
24.62% Other Institutional Investors
18.68% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
KRYS FAQ
What was Krystal Biotech’s price range in the past 12 months?
Krystal Biotech lowest stock price was $93.95 and its highest was $214.98 in the past 12 months.
What is Krystal Biotech’s market cap?
Currently, no data Available
When is Krystal Biotech’s upcoming earnings report date?
Krystal Biotech’s upcoming earnings report date is Nov 04, 2024 which is in 106 days.
How were Krystal Biotech’s earnings last quarter?
Krystal Biotech released its earnings results on May 06, 2024. The company reported $0.03 earnings per share for the quarter, missing the consensus estimate of $0.266 by -$0.236.
Is Krystal Biotech overvalued?
According to Wall Street analysts Krystal Biotech’s price is currently Undervalued.
Does Krystal Biotech pay dividends?
Krystal Biotech does not currently pay dividends.
What is Krystal Biotech’s EPS estimate?
Krystal Biotech’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Krystal Biotech have?
Krystal Biotech has 28,558,440 shares outstanding.
What happened to Krystal Biotech’s price movement after its last earnings report?
Krystal Biotech reported an EPS of $0.03 in its last earnings report, missing expectations of $0.266. Following the earnings report the stock price went down -2.582%.
Which hedge fund is a major shareholder of Krystal Biotech?
Among the largest hedge funds holding Krystal Biotech’s share is Woodline Partners LP. It holds Krystal Biotech’s shares valued at 49M.
---
Krystal Biotech Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$204.00 (0.17% Upside)
$204.00 (0.17% Upside)
Blogger Sentiment
Bullish
KRYS Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 318.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $3.3M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.6%
Last 30 Days ▼ 9.7%
Last 30 Days ▼ 9.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
61.49%
12-Months-Change
Fundamentals
Return on Equity
8.87%
Trailing 12-Months
Asset Growth
60.44%
Trailing 12-Months
Company Description
Krystal Biotech
Krystal Biotech, Inc. is a gene therapy company, which engages in developing and commercializing treatment for patients suffering from dermatological diseases. It developed a gene therapy platform, which company refer to as the Skin TARgeted Delivery platform, or STAR-D platform, that consists of a patent pending engineered viral vector based on herpes simplex virus 1, or HSV-1, and skin-optimized gene transfer technology, to develop off-the-shelf treatments for dermatological diseases for which company believe there are no known effective treatments. The company was founded by Suma M. Krishnan in December 2017 and is headquartered in Pittsburgh, PA.
---
KRYS Company Deck
---
KRYS Earnings Call
Q1 2024
0:00 / 0:00
---
KRYS Stock 12 Month Forecast
Average Price Target
$204.00
▲(0.17% Upside)
Technical Analysis
Best Analysts Covering KRYS
1 Year
1 Year Success Rate
9/9 ratings generated profit
1 Year Average Return
+66.24%
reiterated a buy rating 3 months ago
Copying Joseph Pantginis's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +66.24% per trade.
---